Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.

Autor: Bilgin B; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, Cankaya, 06800, Ankara, Turkey. drbbilgin@hotmail.com., Kuralay Y; Department of Internal Medicine, Erzurum Regional Education and Research Hospital, Erzurum, Turkey., Yucel S; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, Cankaya, 06800, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Apr 26; Vol. 150 (4), pp. 215. Date of Electronic Publication: 2024 Apr 26.
DOI: 10.1007/s00432-023-05529-w
Abstrakt: Background: Inflammation and nutrition are important parameters that significantly affect survival in various malignancies. Prognostic nutritional index (PNI) and modified Glasgow prognostic score (mGPS) can reflect both inflammatory and nutritional conditions. Therefore, we aimed to evaluate the prognostic value of PNI and mGPS in patients who had the targetable mutation and also received targeted therapy.
Materials and Methods: Advanced lung cancer patients with EGFR mutation (mut) and ALK rearrangement were enrolled to study, retrospectively. PNI has with the following formula: 10 × serum albumin (g/dl) + 0.005 × peripheral lymphocyte count (per mm 3 ) and threshold value was accepted as 50. Modified GPS was also calculated using albumin and CRP level and patients were scored as range 0 to 2.
Results: A total of 182 patients enrolled in the study. 132 and 50 of 182 patients had EGFR mut and ALK rearrangement, respectively. PFS was significantly longer in high PNI group in both the EGFR and ALK rearrangement-positive subgroups (P = 0.004 for EGFR mut-positive group; P = 0.017 for ALK rearrangement-positive group). Additionally, PFS was significantly shortened from mGPS 0 to 2 (P =  < 0.001 for EGFR mut-positive group; P = 0.016 for ALK rearrangement-positive group).
Conclusion: Both PNI and mGPS can be used as a reliable, inexpensive, and easily applicable prognostic index in the advanced lung cancer patients who had the targetable mutation and also received targeted therapy.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: